Drug Profile

Teriparatide biosimilar - Alkem Laboratories

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alkem Laboratories
Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
Mechanism of Action Parathyroid hormone replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Registered Postmenopausal osteoporosis

Most Recent Events

04 Feb 2021 Teriparatide biosimilar is available for licensing as of 04 Feb 2021
04 Feb 2021 Registered for Postmenopausal osteoporosis in India (Parenteral)
04 Feb 2021 Enzene Biosciences announces intention to launch teriparatide biosimilar for Postmenopausal osteoporosis in India

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com